The new label states that physicians prescribing the drug should ‘inform patients that events of intracerebral haemorrhage greater than 1cm in diameter have been reported infrequently in patients taking Aduhelm, and that the use of antithrombotic or thrombolytic medications while taking Aduhelm may increase the risk of bleeding in the brain’.
Amyloid-related imaging abnormalities (ARIA), such as brain bleeding and swelling, are known side effects of Aduhelm.
